Structure Therapeutics Inc.
NASDAQ: GPCR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Raymond C. Stevens
- Employees
- 163
- Headquarters
- South San Francisco, United States
- IPO year
- 2023
- Market cap
- $2.8B
- Website
- https://structuretx.com
Loading GPCR…
Loading profile data…Frequently asked questions about GPCR
What does Structure Therapeutics Inc. (GPCR) do?
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small...
Where does GPCR trade?
Structure Therapeutics Inc. (GPCR) trades on the NASDAQ Global Market.
What sector is GPCR in?
Structure Therapeutics Inc. (GPCR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Structure Therapeutics Inc.?
Raymond C. Stevens is the chief executive officer of Structure Therapeutics Inc. (GPCR).
Where is Structure Therapeutics Inc. headquartered?
Structure Therapeutics Inc. is headquartered in United States.
Does GPCR pay a dividend?
Structure Therapeutics Inc. (GPCR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GPCR go public?
Structure Therapeutics Inc. (GPCR) completed its initial public offering in 2023.
Is GPCR an ADR?
Yes — GPCR is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Structure Therapeutics Inc. reporting and dividends follow the underlying issuer.